In this study, we described a patient who carry damaging de novo nonsense variant (c.136G > T;p.Glu46Ter) in IRF2BP1 and was affected with neonatal-onset microcephaly, epilepsy, hypotonia and global developmental delay. Here, IRF2BP1 is linked to microcephaly.